Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:activities |
direct thrombin inhibitor
|
| gptkbp:appointed_by |
healthcare professional
intravenous infusion IV route |
| gptkbp:approves |
gptkb:2000
gptkb:FDA |
| gptkbp:brand |
Argatroban Injection
|
| gptkbp:can_be_used_with |
other anticoagulants
|
| gptkbp:caused_by |
hypotension
|
| gptkbp:clinical_trial |
heparin-induced thrombocytopenia
|
| gptkbp:combatants |
high for thrombin
|
| gptkbp:contraindication |
severe liver disease
active bleeding |
| gptkbp:developed_by |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| gptkbp:dosage_form |
solution for injection
|
| gptkbp:established |
fibrinogen binding to thrombin
|
| https://www.w3.org/2000/01/rdf-schema#label |
argatroban
|
| gptkbp:ingredients |
C19 H24 N4 O5 S
|
| gptkbp:interacts_with |
gptkb:warfarin
|
| gptkbp:is_available_in |
vials
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_effective_against |
preventing clot formation
|
| gptkbp:is_monitored_by |
a PTT
|
| gptkbp:is_part_of |
anticoagulation protocols
thrombosis management |
| gptkbp:is_used_for |
gptkb:peripheral_artery_disease
treating thrombosis |
| gptkbp:is_used_in |
gptkb:hospital
gptkb:deep_vein_thrombosis gptkb:atrial_fibrillation surgical procedures cardiac catheterization pulmonary embolism venous thromboembolism stroke prevention dialysis patients thromboembolic disorders acute coronary syndrome |
| gptkbp:lifespan |
39-51 minutes
|
| gptkbp:metabolism |
liver
|
| gptkbp:premiered_on |
immediate
|
| gptkbp:related_to |
antithrombotic therapy
|
| gptkbp:rounds |
bile
|
| gptkbp:side_effect |
bleeding
|
| gptkbp:suitable_for |
pregnant women
patients with severe renal impairment severe hepatic impairment patients with active bleeding disorders patients with hypersensitivity to the drug |
| gptkbp:type_of |
74863-84-6
|
| gptkbp:used_in |
cardiovascular surgery
percutaneous coronary intervention |
| gptkbp:bfsParent |
gptkb:Angiomax
|
| gptkbp:bfsLayer |
7
|